Quantcast

Latest Eisai Stories

2014-07-10 08:27:50

-- Sales Force Increased to Approximately 600 Sales Specialists -- SAN DIEGO, July 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in...

2014-07-10 08:27:07

LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule of netupitant 300 mg + oral palonosetron 0.50 mg (NEPA), which is licensed to Eisai Inc. in the United States, have been published, together with an accompanying editorial, in the July issue of Annals of Oncology....

2014-07-08 12:28:10

DUBLIN, July 8, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/24nt73/global) has announced the addition of the "Global Alzheimer's Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and...

2014-07-07 16:24:29

THE WOODLANDS, Texas, July 7, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lonnel Coats has been appointed president and chief executive officer effective July 7, 2014. Mr. Coats most recently served as president and chief executive officer of Eisai Inc., the United States subsidiary of Eisai Co., Ltd. Mr. Coats joins Lexicon after 18 years of senior management experience with Eisai. As president and chief executive officer at Eisai, he...

2014-07-03 20:20:02

Tokyo, July 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin") to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should...

2014-07-02 23:03:21

MarketReportsOnline.com adds "Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis" report to its research store. Dallas, Texas (PRWEB) July 02, 2014 Alzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s disease, it still remains a significant area of unmet medical need. Clinical success has...

2014-07-01 16:27:12

LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Global Alzheimer%s Drugs Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_alzheimer_s_drugs_market_2012_2016.html About Alzheimer's DiseaseAlzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and...

2014-06-30 12:26:21

LONDON, June 30, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Seizures - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/seizures_pipeline_review_h1_2013.html Seizures - Pipeline Review, H1 2014 SummaryGlobal Markets Direct's, 'Seizures - Pipeline Review, H1 2014', provides an overview of the Seizures's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Seizures,...

2014-06-26 08:27:36

WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, June 26, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed-dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV), will be presented at the International Symposium on Supportive Care in Cancer. The Multinational Association of Supportive Care in...

2014-06-25 08:32:07

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related